Category: St. Jude Medical
Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.
The CardioMEMS story didn't end when St. Jude Medical (NYSE:STJ) acquired the Georgia-based company in June, paying $375 million for the stake it didn’t already own, valuing the implantable heart failure monitor company at $463 million total.
Here's a look at some of the top legal news stories for medical device companies this week: Judge nixes alleged settlement in Stryker, Biomet poaching spat; Boston Scientific loses bids to exclude testimony in pelvic mesh trials; Occlutech claims another win over St. Jude Medical; Align Tech declares a 'total win' as federal circuit reverses ITC ruling; Report: Medtronic shareholder sues to block Covidien merger
St. Jude Medical informs California state regulators that it's planning to lay off 274 from a facility in Sylmar.
St. Jude Medical (NYSE:STJ) is about to hand out more than 270 pink slips to employees at a facility in Sylmar, Calif., according to a notice filed with the state's Employment Development Dept.
Occlutech says a U.K. court invalidated a patent held by St. Jude Medical covering atrial septal occluder technology.
European approval of next-generation ablation catheter further strengthens St. Jude Medical's fast-growing ablation technology portfolio.
Minnesota medtech giant St. Jude Medical touts 1st use of its FlexAbility ablation catheter after landing approval from European regulators.
European regulators put their stamp of approval on St. Jude Medical's (NYSE:STJ) new FlexAbility ablation catheter, paving the way to 1st use of the next-generation device.
A Danish study of St. Jude Medical's recalled Riata and Riata ST defibrillator leads suggests that the externalization problem that led to the recall worsens over time and is linked to "electrical abnormalities."